EP0866705A4 - Fibrinogenrezeptorantagonisten - Google Patents

Fibrinogenrezeptorantagonisten

Info

Publication number
EP0866705A4
EP0866705A4 EP96936505A EP96936505A EP0866705A4 EP 0866705 A4 EP0866705 A4 EP 0866705A4 EP 96936505 A EP96936505 A EP 96936505A EP 96936505 A EP96936505 A EP 96936505A EP 0866705 A4 EP0866705 A4 EP 0866705A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
fibrinogen receptor
fibrinogen
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96936505A
Other languages
English (en)
French (fr)
Other versions
EP0866705A1 (de
Inventor
Ben C Askew
George D Hartman
Mark E Duggan
Steven D Young
John H Hutchinson
John S Wai
Melissa S Egbertson
Laura M Vassallo
Laura A Libby
Nathan C Ihle
Amy E Krause
Wasyl Halczenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603371.7A external-priority patent/GB9603371D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0866705A1 publication Critical patent/EP0866705A1/de
Publication of EP0866705A4 publication Critical patent/EP0866705A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP96936505A 1995-10-19 1996-10-15 Fibrinogenrezeptorantagonisten Withdrawn EP0866705A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US560295P 1995-10-19 1995-10-19
US5602P 1995-10-19
GBGB9603371.7A GB9603371D0 (en) 1996-02-16 1996-02-16 Fibrinogen receptor antagonists
GB9603371 1996-02-16
PCT/US1996/016491 WO1997014417A1 (en) 1995-10-19 1996-10-15 Fibrinogen receptor antagonists

Publications (2)

Publication Number Publication Date
EP0866705A1 EP0866705A1 (de) 1998-09-30
EP0866705A4 true EP0866705A4 (de) 1999-03-03

Family

ID=26308744

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96936505A Withdrawn EP0866705A4 (de) 1995-10-19 1996-10-15 Fibrinogenrezeptorantagonisten

Country Status (5)

Country Link
EP (1) EP0866705A4 (de)
JP (1) JPH11513686A (de)
AU (1) AU713247B2 (de)
CA (1) CA2234967A1 (de)
WO (1) WO1997014417A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889023A (en) * 1996-05-10 1999-03-30 Merck & Co., Inc. Fibrinogen receptor antagonist
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
NZ500353A (en) 1997-04-14 2002-02-01 Cor Therapeutics Inc Cyclic diaza compounds that are selective inhibitors of factor Xa
AU747531B2 (en) 1997-04-14 2002-05-16 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
AU6896398A (en) 1997-04-14 1998-11-11 Cor Therapeutics, Inc. Selective factor xa inhibitors
AU741099B2 (en) * 1997-04-14 2001-11-22 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
ES2224620T3 (es) * 1998-03-23 2005-03-01 Aventis Pharmaceuticals Inc. Derivados de piperidinilo y n-aminopiperidinilo.
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6645968B2 (en) 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7225170B1 (en) 2000-07-27 2007-05-29 Pitney Bowes Inc. Postage metering system for use with business reply mail
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
EP1987009A1 (de) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cycloharnstoffverbindung als calciumkanalblocker
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
EP2413701A4 (de) 2009-03-31 2012-10-03 Univ Vanderbilt Sulfonyl-azetidin-3-yl-methylamin-amidanaloga als glyt1-hemmer, verfahren zu ihrer herstellung sowie ihre verwendung zur behandlung psychiatrischer erkrankungen

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372486A2 (de) * 1988-12-08 1990-06-13 F. Hoffmann-La Roche Ag Neue Benzoesäure- und Phenylessigsäurederivate, ihre Herstellung und Verwendung als Heilmittel
EP0478328A1 (de) * 1990-09-27 1992-04-01 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagonisten
EP0478362A2 (de) * 1990-09-27 1992-04-01 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagonisten
EP0512829A1 (de) * 1991-05-07 1992-11-11 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagonisten
EP0512831A1 (de) * 1991-05-07 1992-11-11 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagonisten
EP0540334A1 (de) * 1991-10-29 1993-05-05 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagoniste
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995025088A1 (en) * 1994-03-14 1995-09-21 Merck & Co., Inc. Pyridyl ethylation of lactam derivatives
WO1995025101A1 (en) * 1994-03-14 1995-09-21 Merck & Co., Inc. Pyridil ethylation of lactams
WO1996019221A1 (en) * 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372486A2 (de) * 1988-12-08 1990-06-13 F. Hoffmann-La Roche Ag Neue Benzoesäure- und Phenylessigsäurederivate, ihre Herstellung und Verwendung als Heilmittel
EP0478328A1 (de) * 1990-09-27 1992-04-01 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagonisten
EP0478362A2 (de) * 1990-09-27 1992-04-01 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagonisten
US5455243A (en) * 1991-05-07 1995-10-03 Merck & Co., Inc. Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets
EP0512829A1 (de) * 1991-05-07 1992-11-11 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagonisten
EP0512831A1 (de) * 1991-05-07 1992-11-11 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagonisten
EP0540334A1 (de) * 1991-10-29 1993-05-05 Merck & Co. Inc. Fibrinogen-Rezeptor-Antagoniste
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995025088A1 (en) * 1994-03-14 1995-09-21 Merck & Co., Inc. Pyridyl ethylation of lactam derivatives
WO1995025101A1 (en) * 1994-03-14 1995-09-21 Merck & Co., Inc. Pyridil ethylation of lactams
WO1996019221A1 (en) * 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9714417A1 *

Also Published As

Publication number Publication date
EP0866705A1 (de) 1998-09-30
JPH11513686A (ja) 1999-11-24
AU713247B2 (en) 1999-11-25
CA2234967A1 (en) 1997-04-24
AU7432296A (en) 1997-05-07
WO1997014417A1 (en) 1997-04-24

Similar Documents

Publication Publication Date Title
NO972016D0 (no) Indolyl-Y-reseptorantagonister
DE69734833D1 (de) Vitronektin rezeptor antagonisten
FI970107A7 (fi) Heterosyklisiä takykiniinireseptoriantagonisteja
FI955223A7 (fi) Adheesioreseptoriantagonisteja
BR9508178A (pt) Antagonistas de receptor de vitronectina
BR9612381A (pt) Antagonistas receptores vitronectina
NO983003D0 (no) Vitronectin-reseptor-antagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
FI934894A7 (fi) Fibrinogeenireseptorin antagonisteja
FI914533A7 (fi) Fibrinogeenireseptoriantagonisteja
EP0810994A4 (de) Fibrinogen-rezeptor-antagonisten
FI960953A0 (fi) Endoteliinireseptoriantagonisteja
MX9101311A (es) Antagonistas receptores de fibrinogeno
ID16742A (id) Antagonis reseptor endotelin
FI960516A7 (fi) Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja
DE59610900D1 (de) Adhäsionsrezeptor-Antagonisten
AU1441695A (en) Fibrinogen receptor antagonists
ID24726A (id) Antagonis-antagonis reseptor trombin
NO950606D0 (no) Adhesjonsreseptor-antagonister
FI953916A7 (fi) Fibrinogeenireseptoriantagonisteja
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
ID24162A (id) Antagonis-antagonis reseptor vitronektin
FI955351A7 (fi) Tarttumisreseptoriantagonistit
BR9507220A (pt) Antagonistas de receptores de endotelina

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980519

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20010417

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011030